Clinical trial
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
NCT07307287 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 20, 2025
- Completion date
- December 31, 2027
- Enrollment
- 30 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
early breast cancer, her2-postive breast cancer, hr+ breast cancer, locally advanced breast cancer, shr-a1811